New Relevant Evidence in Cholangiocarcinoma Biology and Characterization DOI Open Access

N. M. Porro,

Elena Spínola-Lasso, Mirella Pastore

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(24), P. 4239 - 4239

Published: Dec. 19, 2024

Among solid tumors, cholangiocarcinoma (CCA) emerges as one of the most difficult to eradicate. The silent and asymptomatic nature this tumor, particularly in its early stages, well high heterogeneity at genomic, epigenetic, molecular levels delay diagnosis, significantly compromising efficacy current therapeutic options thus contributing a dismal prognosis. Extensive research has been conducted on pathobiology CCA, recent advances have made classification characterization new targets. Both targeted therapy immunotherapy emerged effective safe strategies for various types cancers, demonstrating potential benefits advanced CCA. Furthermore, deeper comprehension cellular components tumor microenvironment (TME) opened up possibilities innovative treatment methods. This review discusses evidence biology highlighting novel possible druggable

Language: Английский

Design, synthesis, and biological evaluation of novel FGFR1 PROTACs DOI
Yuwei Wang, Yuhui Gao, Cheng Wang

et al.

Bioorganic Chemistry, Journal Year: 2024, Volume and Issue: 155, P. 108109 - 108109

Published: Dec. 30, 2024

Language: Английский

Citations

1
Design, Synthesis and Biological Evaluation of 5-Amino-1h-Pyrazole-4-Carboxamide Derivatives as Pan-Fgfr Covalent Inhibitors DOI

Wuqing Deng,

Xiaojuan Chen, Hong Liang

et al.

Published: Jan. 1, 2024

Download This Paper Open PDF in Browser Add to My Library Share: Permalink Using these links will ensure access this page indefinitely Copy URL DOI

Language: Английский

Citations

0
Diagnostik und Therapie von hepatobiliären Tumoren DOI
Alexander Philipp

InFo Hämatologie + Onkologie, Journal Year: 2024, Volume and Issue: 27(6), P. 36 - 44

Published: June 1, 2024

Citations

0
New Relevant Evidence in Cholangiocarcinoma Biology and Characterization DOI Open Access

N. M. Porro,

Elena Spínola-Lasso, Mirella Pastore

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(24), P. 4239 - 4239

Published: Dec. 19, 2024

Among solid tumors, cholangiocarcinoma (CCA) emerges as one of the most difficult to eradicate. The silent and asymptomatic nature this tumor, particularly in its early stages, well high heterogeneity at genomic, epigenetic, molecular levels delay diagnosis, significantly compromising efficacy current therapeutic options thus contributing a dismal prognosis. Extensive research has been conducted on pathobiology CCA, recent advances have made classification characterization new targets. Both targeted therapy immunotherapy emerged effective safe strategies for various types cancers, demonstrating potential benefits advanced CCA. Furthermore, deeper comprehension cellular components tumor microenvironment (TME) opened up possibilities innovative treatment methods. This review discusses evidence biology highlighting novel possible druggable

Language: Английский

Citations

0